Read More

Scribe Therapeutics Announced That Sanofi Has Exercised Its Option For A Second Target As Part Of The Companies’ Research Collaboration To Develop In Vivo CRISPR-based Therapeutics

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to

SNY